

September 27, 2021

News Release

Company: Olympus Corporation
Yasuo Takeuchi, Director, Representative Executive Officer, President and CEO
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations
TEL: +81-3-3340-2111

**Notice Regarding Establishment of a Corporate Venture Capital Fund
“Olympus Innovation Ventures”**

Olympus Corporation ("Olympus") hereby announces today that it has decided to establish Olympus Innovation Ventures, LLC (“Olympus Ventures”) as a corporate venture capital fund.

1. Background and Purpose

Olympus announced, on November 6, 2019, its new corporate strategy ("Corporate Strategy") to achieve growth as a global medical technology ("medtech") company. Under this Corporate Strategy, we aim to sustain an annual revenue growth rate of 5-6% based on organic growth through investment in existing businesses and functional enhancements, mainly in the medical field, as well as M&A and other investments in line with our business strategy.

In recent years, the pace of innovation has been accelerating, and new trends such as digital, AI and robotics are shifting the medtech landscape. In order to take advantage of these opportunities and to create opportunities for us to grow, we have decided to establish a corporate venture capital fund, that will allow us to form relationships with early stage companies and help nurture partnerships with relevant and compelling entrepreneurial teams.

2. Overview of Olympus Ventures

(1) Company Name	Olympus Innovation Ventures, LLC
(2) Address	800 West Park Drive, Westborough, MA 01581, United States
(3) Title and Name of representative	President Nacho Abia
(4) Description of business	Investment in and support to external opportunities
(5) Total Initial Investment Amount	USD 50 million (approximately JPY 5.5 billion (Note1))
(6) Date of incorporation	October 5, 2021(Plan)
(7) Investors and investment ratios	Olympus Corporation of the Americas (Note2) 100%
(8) Fiscal year	The fiscal year of Olympus Ventures shall end on March 31.

(9) Relationship between Olympus and Olympus Ventures	Capital relationship	Olympus Ventures will be established through a 100% investment by a consolidated subsidiary of Olympus.
	Personnel relationship	Executive officers of Olympus and an employee of a consolidated subsidiary of Olympus will concurrently serve as officers of Olympus Ventures.
	Transactional relationship	A business relationship will be occurred for the services provided by Olympus Ventures.

(Note1) Calculated at the exchange rate of JPY 109.90 per USD (exchange rate as of the end of August 2021).

(Note2) Olympus Corporation of the Americas is a consolidated subsidiary of Olympus.

3. Future Opportunities

Olympus will initially commit a total of USD 50 million over five years for Olympus Ventures to search, identify, vet and invest in early stage companies with differentiated technologies. Olympus Ventures will deliver the following benefits to us:

- (1) Build a pipeline of future M&A targets
- (2) Spot critical trends in technology, medicine, and care delivery
- (3) Identify promising new markets for future growth
- (4) Generate financial return on invested capital
- (5) Raise Olympus' profile in the Medtech innovation ecosystem

4. Future Outlook

Olympus believe that the establishment of Olympus Ventures will not be a material impact on the financial results for the year ending March 31, 2022. Olympus will promptly provide notice as soon as additional items to be disclosed have arisen.

For more information about Olympus Ventures please contact:

Olympus Corporation of the Americas

Christos Monovoukas

Vice President, Global M&A Leader / Business Development

christos.monovoukas@olympus.com

800 West Park Drive, Westborough, MA 01581 United States